Table 4.
Cross trial comparison.
| Median Survival (Months) | 95% CI | ||
|---|---|---|---|
| Conroy et al. (2011) [43], multicenter, randomized, phase 2–3 trial comparing FOLFIRINOX to gemcitabine monotherapy |
11.1 | 9.0 to 13.1 | |
| Von Hoff et al. (2013) [44], multicenter, open-label, randomized, phase 3 study comparing gemcitabine/nab-paclitaxel to gemcitabine monotherapy |
8.5 | 7.9 to 9.5 | |
| Hegewisch-Becker et al. (2019) [46], prospective clinical cohort study using different regimens (German TPK) |
9.2 | 8.5 to 10.0 | |
| Klein-Brill et al. (2022) [45], retrospective cohort study |
9.3 | 8.7 to 9.8 | |
| Wainberg et al. (2023) [42], multicenter, open-label, randomized, phase 3 study comparing NALIRIFOX to gemcitabine/nab-paclitaxel |
11.1 | 10.0 to 12.1 | |
| Current data | |||
| Chemotherapy alone | 8.6 | 4.7 to 15.4 | |
| Chemotherapy + only mistletoe | 11.2 | 7.1 to 14.2 | |
| Chemotherapy + combination mistletoe/hyperthermia | 18.9 | 15.2 to 24.5 | |
CI, confidence interval; TPK, Tumour Registry Pancreatic Cancer.